NightHawk Biosciences Confirms NYSE American Listing for Common Stock

TL;DR

**NHWK's common stock is officially listed on NYSE American, ensuring market access.**

AI Summary

NightHawk Biosciences, Inc. (NHWK) filed an 8-K on January 8, 2024, to disclose that its Common Stock, with a par value of $0.0002 per share, is registered on the NYSE American LLC. This filing also confirms the company's business address as 627 Davis Drive, Suite 300, Morrisville, North Carolina 27560. This matters to investors as it reaffirms the listing of their shares on a major exchange, providing liquidity and transparency for their investment.

Why It Matters

This filing confirms the continued listing of NightHawk Biosciences' common stock on the NYSE American LLC, which is crucial for maintaining investor confidence and market accessibility.

Risk Assessment

Risk Level: low — This filing is a routine disclosure confirming existing information and does not introduce new financial risks or operational changes.

Analyst Insight

A smart investor would note this filing as a routine confirmation of listing status, reinforcing the stock's market presence without indicating any immediate need for action based solely on this information.

Key Numbers

• $0.0002 — Par Value per Share (The stated par value of NightHawk Biosciences' Common Stock.)

Key Players & Entities

• NightHawk Biosciences, Inc. (company) — the registrant filing the 8-K
• NYSE American LLC (company) — the exchange where NightHawk Biosciences' common stock is registered
• $0.0002 (dollar_amount) — par value per share of Common Stock

Forward-Looking Statements

• NightHawk Biosciences will continue to be listed on the NYSE American LLC. (NightHawk Biosciences, Inc.) — high confidence, target: Ongoing

FAQ

Key Financial Figures

• $0.0002 — nge on which registered Common Stock, $0.0002 par value per share NHWK NYSE America

Filing Documents

• nhwk_8k.htm (8-K) — 29KB
• ex99x1.htm (EX-99.1) — 14KB
• 0001079973-24-000037.txt ( ) — 259KB
• nhwk-20240108.xsd (EX-101.SCH) — 3KB
• nhwk-20240108_def.xml (EX-101.DEF) — 26KB
• nhwk-20240108_lab.xml (EX-101.LAB) — 36KB
• nhwk-20240108_pre.xml (EX-101.PRE) — 25KB
• nhwk_8k_htm.xml (XML) — 5KB

01. Regulation

Item 7.01. Regulation FD Disclosure. On January 8, 2024, NightHawk Biosciences, Inc. (the "Company"), issued a press release announcing that it is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01 Other Items

Item 8.01 Other Items On January 8, 2024, the Company issued a press release announcing that it is changing the name of the Company to Scorpius Holdings, Inc., to better reflect the Company's successful shift into a pure-play, large molecule biomanufacturing CDMO. The Company will continue to operate its CDMO within the Scorpius BioManufacturing, Inc. subsidiary. In connection with the name change, the Company's ticker will change to SCPX.

01 Financial Statements and

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated January 8, 2024 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 8, 2024 NightHawk Biosciences, Inc. By: /s/ Jeff Wolf Name: Jeff Wolf Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR